Flu drug still not worth prescribing, experts sayBMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7283.382/a (Published 17 February 2001) Cite this as: BMJ 2001;322:382
- Zosia Kmietowicz
The National Institute for Clinical Excellence has been criticised for giving doctors the go-ahead to prescribe the antiflu drug zanamivir (Relenza).
The Drug and Therapeutics Bulletin stated this week that there was still insufficient proof that zanamivir was effective in the group of patients for which the drug could be prescribedthose considered to be “at risk” of flu complications and who …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial